VYNE Therapeutics (VYNE) Enterprise Value Growth (3y) (2019 - 2026)
VYNE Therapeutics (VYNE) Enterprise Value Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -619.24% |
| Dec 31, 2025 | -488.14% |
| Jun 30, 2025 | 2.53% |
| Mar 31, 2025 | 0.15% |
| Dec 31, 2024 | -366.74% |
| Sep 30, 2024 | -10.30% |
| Jun 30, 2024 | -405.40% |
| Mar 31, 2024 | 10.41% |
| Dec 31, 2023 | -221.75% |
| Sep 30, 2023 | 90.95% |
| Jun 30, 2023 | 40.73% |
| Mar 31, 2023 | 62.55% |
| Dec 31, 2022 | 26.17% |
| Sep 30, 2022 | 28.62% |
| Jun 30, 2022 | 19.94% |
| Mar 31, 2022 | 13.70% |
| Dec 31, 2021 | 80.91% |
| Sep 30, 2021 | 30.02% |
| Jun 30, 2021 | 84.21% |
| Mar 31, 2021 | 8.46% |